The gp 130 family cytokines IL‐6, LIF and OSM but not IL‐11 can reverse the anti‐proliferative effect of dexamethasone on human myeloma cells
- 1 July 1995
- journal article
- Published by Wiley in British Journal of Haematology
- Vol. 90 (3) , 707-710
- https://doi.org/10.1111/j.1365-2141.1995.tb05605.x
Abstract
In order to understand the mechanisms supporting steroid escape in patients with multiple myeloma (MM), three IL-6 autocrine human myeloma cell lines, LP1, OPM2 and L363, have been treated with dexamethasone in the presence or absence of cytokines belonging to the gp 130 family: IL-6, LIF, OSM and IL-11. With pharmacological doses of dexamethasone, a dramatic growth arrest was observed in all the cell lines. IL-6 completely reversed this inhibition. Of note, this IL-6 induced reversion was still seen with very low amounts of IL-6 (12 pg/ml). Finally, whereas LIF and OSM had clear growth-promoting effects on OPM2 only, both cytokines (but not IL-11) reversed the dexamethasone-induced growth arrest in all the cell lines. Therefore the high levels of IL-6 (ng/ml) observed in the MM intermediate milieu and the putative presence of LIF and OSM can easily counteract the effects of dexamethasone in vivo.Keywords
This publication has 12 references indexed in Scilit:
- Interleukin-6 prevents dexamethasone-induced myeloma cell deathBlood, 1994
- Ciliary neurotropic factor, interleukin 11, leukemia inhibitory factor, and oncostatin M are growth factors for human myeloma cell lines using the interleukin 6 signal transducer gp130.The Journal of Experimental Medicine, 1994
- Oncostatin M, leukemia inhibitory factor, and interleukin 6 induce the proliferation of human plasmacytoma cells via the common signal transducer, gp130.The Journal of Experimental Medicine, 1994
- Primary dexamethasone treatment of multiple myelomaBlood, 1992
- Lack of a role of interleukin 11 in the growth of multiple myelomaLeukemia Research, 1992
- On the mechanism for efficient repression of the interleukin-6 promoter by glucocorticoids: enhancer, TATA box, and RNA start site (Inr motif) occlusion.Molecular and Cellular Biology, 1990
- Effect of glucocorticoids on the biologic activities of myeloma cells: inhibition of interleukin-1 beta osteoclast activating factor-induced bone resorptionBlood, 1990
- Serum levels of interleukin 6, a potent myeloma cell growth factor, as a reflect of disease severity in plasma cell dyscrasias.Journal of Clinical Investigation, 1989
- Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomasNature, 1988
- Effect of cell cycle position on dexamethasone binding by mouse and human lymphoid cell lines: correlation between an increase in dexamethasone binding during S phase and dexamethasone sensitivityBlood, 1984